Trade Zai Lab Limited - ZLAB CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.21 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 15.06 |
| Open | 15.81 |
| 1-Year Change | -55.96% |
| Day's Range | 15.41 - 15.86 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2024 | 15.58 | -0.01 | -0.06% | 15.59 | 15.97 | 15.34 |
| Apr 23, 2024 | 15.06 | 0.08 | 0.53% | 14.98 | 15.48 | 14.84 |
| Apr 22, 2024 | 14.88 | 0.42 | 2.90% | 14.46 | 15.18 | 14.36 |
| Apr 19, 2024 | 13.99 | 0.13 | 0.94% | 13.86 | 14.14 | 13.79 |
| Apr 18, 2024 | 14.12 | 0.61 | 4.52% | 13.51 | 14.16 | 13.34 |
| Apr 17, 2024 | 13.64 | -0.54 | -3.81% | 14.18 | 14.18 | 13.57 |
| Apr 16, 2024 | 14.27 | 0.33 | 2.37% | 13.94 | 14.50 | 13.94 |
| Apr 15, 2024 | 14.07 | 0.09 | 0.64% | 13.98 | 14.36 | 13.88 |
| Apr 12, 2024 | 14.24 | -0.40 | -2.73% | 14.64 | 14.82 | 14.15 |
| Apr 11, 2024 | 14.94 | -0.29 | -1.90% | 15.23 | 15.27 | 14.91 |
| Apr 10, 2024 | 15.33 | -0.37 | -2.36% | 15.70 | 15.79 | 15.01 |
| Apr 9, 2024 | 15.88 | 0.18 | 1.15% | 15.70 | 16.06 | 15.54 |
| Apr 8, 2024 | 15.37 | -0.04 | -0.26% | 15.41 | 15.65 | 15.13 |
| Apr 5, 2024 | 15.44 | 0.20 | 1.31% | 15.24 | 15.79 | 15.09 |
| Apr 4, 2024 | 15.35 | -0.20 | -1.29% | 15.55 | 15.72 | 15.22 |
| Apr 3, 2024 | 15.82 | 0.18 | 1.15% | 15.64 | 15.95 | 15.38 |
| Apr 2, 2024 | 15.96 | -0.13 | -0.81% | 16.09 | 16.40 | 15.74 |
| Apr 1, 2024 | 16.63 | 0.69 | 4.33% | 15.94 | 16.66 | 15.87 |
| Mar 28, 2024 | 15.92 | -0.33 | -2.03% | 16.25 | 16.27 | 15.86 |
| Mar 27, 2024 | 16.10 | -0.03 | -0.19% | 16.13 | 16.54 | 15.47 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Zai Lab Limited Company profile
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.| Industry: | Biopharmaceuticals |
4560 Jinke Road
Bldg. 1, 4/F
SHANGHAI
SHANGHAI 201210
CN
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com